| Integrative clinical genomics of advanced prostate cancer D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ... Cell 161 (5), 1215-1228, 2015 | 3965 | 2015 |
| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2397 | 2015 |
| Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... The Lancet 387 (10024), 1163-1177, 2016 | 2214 | 2016 |
| Abiraterone for prostate cancer not previously treated with hormone therapy ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ... New England Journal of Medicine 377 (4), 338-351, 2017 | 1906 | 2017 |
| Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ... The Lancet 392 (10162), 2353-2366, 2018 | 1196 | 2018 |
| Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven G Attard, AHM Reid, TA Yap, F Raynaud, M Dowsett, S Settatree, ... Journal of clinical oncology 26 (28), 4563-4571, 2008 | 1090 | 2008 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 886* | 2018 |
| Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer G Attard, AHM Reid, R A'Hern, C Parker, NB Oommen, E Folkerd, ... Journal of clinical oncology 27 (23), 3742-3748, 2009 | 735 | 2009 |
| Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer G Attard, JF Swennenhuis, D Olmos, AHM Reid, E Vickers, R A'Hern, ... Cancer research 69 (7), 2912-2918, 2009 | 690 | 2009 |
| Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer G Attard, J Clark, L Ambroisine, G Fisher, G Kovacs, P Flohr, D Berney, ... Oncogene 27 (3), 253-263, 2008 | 568 | 2008 |
| Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate AHM Reid, G Attard, DC Danila, NB Oommen, D Olmos, PC Fong, ... Journal of clinical oncology 28 (9), 1489-1495, 2010 | 511 | 2010 |
| Plasma AR and abiraterone-resistant prostate cancer A Romanel, DG Tandefelt, V Conteduca, A Jayaram, N Casiraghi, ... Science translational medicine 7 (312), 312re10-312re10, 2015 | 479 | 2015 |
| Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ... Annals of Oncology 30 (12), 1992-2003, 2019 | 429 | 2019 |
| Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Y Loriot, D Bianchini, E Ileana, S Sandhu, A Patrikidou, C Pezaro, ... Annals of oncology 24 (7), 1807-1812, 2013 | 424 | 2013 |
| Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer HI Scher, G Heller, A Molina, G Attard, DC Danila, X Jia, W Peng, ... Journal of clinical oncology 33 (12), 1348-1355, 2015 | 415 | 2015 |
| Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 S Gillessen, A Omlin, G Attard, JS de Bono, E Efstathiou, K Fizazi, ... Annals of Oncology 26 (8), 1589-1604, 2015 | 405 | 2015 |
| Tumor clone dynamics in lethal prostate cancer S Carreira, A Romanel, J Goodall, E Grist, R Ferraldeschi, S Miranda, ... Science translational medicine 6 (254), 254ra125-254ra125, 2014 | 398 | 2014 |
| ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group J Pascual, G Attard, FC Bidard, G Curigliano, L de Mattos-Arruda, ... Annals of Oncology 33 (8), 750-768, 2022 | 390 | 2022 |
| Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer AHM Reid, G Attard, L Ambroisine, G Fisher, G Kovacs, D Brewer, J Clark, ... British journal of cancer 102 (4), 678-684, 2010 | 327 | 2010 |
| Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer G Attard, AHM Reid, RJ Auchus, BA Hughes, AM Cassidy, E Thompson, ... The Journal of Clinical Endocrinology & Metabolism 97 (2), 507-516, 2012 | 323 | 2012 |
